Published in Nat Rev Gastroenterol Hepatol on April 01, 2011
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology (2012) 1.48
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.26
Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc (2014) 1.21
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget (2014) 1.14
Atypical presentation of an advanced obstructive biliary cancer without jaundice. Am J Case Rep (2013) 1.09
miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol (2014) 0.99
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol (2014) 0.96
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res (2014) 0.93
New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol (2013) 0.92
Perihilar cholangiocarcinoma: a surgeon's viewpoint on current topics. J Gastroenterol (2012) 0.92
Annexin A1: A new immunohistological marker of cholangiocarcinoma. World J Gastroenterol (2013) 0.91
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer (2013) 0.90
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol (2013) 0.90
Comparison of uncovered and covered stents for the treatment of malignant duodenal obstruction caused by pancreaticobiliary cancer. Surg Endosc (2013) 0.89
Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One (2012) 0.89
Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. J Cancer Res Clin Oncol (2013) 0.87
Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surg Today (2014) 0.86
Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol (2015) 0.85
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol (2013) 0.84
Phenethyl isothiocyanate induces calcium mobilization and mitochondrial cell death pathway in cholangiocarcinoma KKU-M214 cells. BMC Cancer (2013) 0.83
Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J Extracell Vesicles (2015) 0.83
Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep (2016) 0.83
Comparison between uncovered and covered self-expandable metal stent placement in malignant duodenal obstruction. World J Gastroenterol (2015) 0.82
Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology (2016) 0.82
Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness. Mol Pharm (2016) 0.81
MicroRNA-224 Induces G1/S Checkpoint Release in Liver Cancer. J Clin Med (2015) 0.81
Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag (2011) 0.81
The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget (2015) 0.81
The Preoperative Assessment of Hepatic Tumours: Evaluation of UK Regional Multidisciplinary Team Performance. HPB Surg (2013) 0.80
The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med (2015) 0.80
Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expr (2014) 0.80
Extracellular vesicle noncoding RNA: new players in the diagnosis and pathogenesis of cholangiocarcinoma. Hepatology (2014) 0.80
Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. PLoS One (2014) 0.79
Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 0.79
Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J Cancer (2015) 0.78
Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma. J Nanobiotechnology (2015) 0.78
The significance of genetics for cholangiocarcinoma development. Ann Transl Med (2013) 0.78
Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma. Onco Targets Ther (2016) 0.78
Over-expression of nerve growth factor-β in human cholangiocarcinoma QBC939 cells promote tumor progression. PLoS One (2013) 0.78
Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res (2015) 0.77
Prognostic significance of microRNA-203 in cholangiocarcinoma. Int J Clin Exp Pathol (2015) 0.76
Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. Int J Mol Sci (2016) 0.76
Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. Int J Oncol (2015) 0.76
Clonorchis sinensis infestation promotes three-dimensional aggregation and invasion of cholangiocarcinoma cells. PLoS One (2014) 0.76
Phenethyl isothiocyanate induces apoptosis of cholangiocarcinoma cells through interruption of glutathione and mitochondrial pathway. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.76
Tumor growth effects of rapamycin on human biliary tract cancer cells. Eur J Med Res (2012) 0.76
Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget (2016) 0.76
Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. Clin Epigenetics (2016) 0.75
Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg (2013) 0.75
The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. PLoS One (2016) 0.75
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol (2016) 0.75
Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma. Onco Targets Ther (2017) 0.75
Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis. J Cancer (2017) 0.75
A long survivor with local relapse of hilar cholangiocarcinoma after R1 surgery treated with chemoradiotherapy: a case report and literature review. Surg Case Rep (2016) 0.75
Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development. Histochem Cell Biol (2012) 0.75
Mandibular metastasis of cholangiocarcinoma: A case report. Imaging Sci Dent (2015) 0.75
Preneoplastic conditions underlying bile duct cancer. Langenbecks Arch Surg (2012) 0.75
Biliary tract cancer stem cells - translational options and challenges. World J Gastroenterol (2017) 0.75
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis (2016) 0.75
Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int (2016) 0.75
Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures. World J Gastrointest Endosc (2015) 0.75
Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells. Oncol Lett (2017) 0.75
Cul4B is a novel prognostic marker in cholangiocarcinoma. Oncol Lett (2017) 0.75
Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. Ann Hepatol (2017) 0.75
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
ADENOCARCINOMA OF THE HEPATIC DUCT AT ITS BIFURCATION WITHIN THE PORTA HEPATIS. AN UNUSUAL TUMOR WITH DISTINCTIVE CLINICAL AND PATHOLOGICAL FEATURES. Am J Med (1965) 4.22
Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet (1975) 4.17
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol (1996) 4.00
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Management strategies in resection for hilar cholangiocarcinoma. Ann Surg (1992) 3.69
Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology (2005) 3.24
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Extended resections for hilar cholangiocarcinoma. Ann Surg (1999) 2.93
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Worldwide trends in mortality from biliary tract malignancies. BMC Cancer (2002) 2.61
Choledochal cyst disease. A changing pattern of presentation. Ann Surg (1994) 2.33
Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol (2006) 2.29
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology (1998) 2.19
Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc (2006) 2.11
Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg (2003) 2.04
Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg (2006) 2.03
Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg (2003) 2.00
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Systemic therapy for biliary tract cancers. Oncologist (2008) 1.98
Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer (2000) 1.98
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol (2007) 1.96
Surgical management of hilar cholangiocarcinoma. Ann Surg (2005) 1.80
Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg (2006) 1.76
An industry-wide epidemiologic study of vinyl chloride workers, 1942-1982. Am J Ind Med (1991) 1.75
Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control (2001) 1.74
Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg (1994) 1.72
Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg (2010) 1.69
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg (2006) 1.64
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg (2003) 1.59
Cholangiocarcinoma: update and future perspectives. Dig Liver Dis (2010) 1.58
Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58
Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics (2009) 1.55
Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol (2008) 1.54
Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol (2007) 1.51
Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg (2010) 1.51
AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer (2010) 1.44
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci (2009) 1.44
Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol (2010) 1.41
Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology (2006) 1.40
Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27
Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol (2005) 1.26
Late development of bile duct cancer after sphincteroplasty: a ten- to twenty-two-year follow-up study. Surgery (1997) 1.19
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nippon Med Sch (2009) 1.18
Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy (2005) 1.18
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer (2010) 1.18
Identification and characterization of microRNAs in Clonorchis sinensis of human health significance. BMC Genomics (2010) 1.16
The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg (2005) 1.16
Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol (2005) 1.15
Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol (2009) 1.15
What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist (2006) 1.14
Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol (2010) 1.12
Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol (2010) 1.09
Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer (2010) 1.08
Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am (2009) 1.08
Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today (2005) 1.08
Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol (2010) 1.07
Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol (2006) 1.07
Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann Surg (2010) 1.06
Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr Opin Gastroenterol (2009) 1.06
Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med (2010) 1.06
Thorotrast-associated cholangiocarcinoma: an epidemiologic and clinicopathologic study. Cancer (1982) 1.05
Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys (2005) 1.05
Hepatolithiasis associated with cholangiocarcinoma. Br J Surg (1997) 1.03
Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use. Cancer (1987) 1.03
Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. J Gastrointest Surg (2011) 1.02
Asbestos bodies in a bile duct cancer after occupational exposure. Environ Res (1983) 1.01
Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2009) 1.00
Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment. World J Gastroenterol (2006) 1.00
Preoperative biliary drainage for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg (2008) 1.00
Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci (2005) 0.99
Endoscopic techniques to diagnose and manage biliary tumors. J Clin Oncol (2005) 0.99
Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys (2010) 0.99
Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol Clin Biol (2010) 0.98
Liver resection for hilar cholangiocarcinoma: in-hospital mortality and longterm survival. J Am Coll Surg (2002) 0.97
Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol (2007) 0.97
Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) (2006) 0.95
Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol (2010) 0.95
Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci (2010) 0.93
A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol (2009) 0.93
Staging of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol (2010) 0.90
R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int (2010) 0.88
The concept of perihilar cholangiocarcinoma is valid. Br J Surg (2009) 0.87
Cholangiocarcinoma: risk factors and clinical presentation. Eur Rev Med Pharmacol Sci (2010) 0.86
Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev (2009) 0.84
A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma. Am J Gastroenterol (2006) 0.83
Spectrum of benign lesions mimicking a malignant stricture at the liver hilum. Rev Recent Clin Trials (2009) 0.83
Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol (2006) 0.81
Pre-operative biliary drainage in hilar cholangiocarcinoma, benefits and risks, single center experience. Hepatogastroenterology (2010) 0.79